Picture loading failed.

Anti-CD274;CTLA4 therapeutic antibody (Pre-made Erfonrilimab biosimilar,Bispecific Single Domains (VH-VH'-CH)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-194-1mg 1mg Inquiry
GMP-Bios-ab-194-10mg 10mg Inquiry
GMP-Bios-ab-194-100mg 100mg Inquiry
GMP-Bios-ab-194-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD274;CTLA4 therapeutic antibody (Pre-made Erfonrilimab biosimilar,Bispecific Single Domains (VH-VH'-CH))
INN Name Erfonrilimab
FormatBispecific Single Domains (VH-VH'-CH)
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCna;na
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;6rqm:B
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Triple-negative breast cancer;Esophageal carcinoma
Conditions Discontinuedna
Development Techna